That stiffness that greets you every morning.

That stiffness that greets you every morning.

Hemp, preserved close to how it grows, nourishes the body's own path back to ease. That's CBDA, and it's what most hemp products lose before they reach you.

See how it works

100-day guarantee

Keep the opened bottle, return the rest

Third-party tested

Every batch, potency and purity

Free US shipping over $70

Ships in 2 business days

Founded by a PhD and an MD

Formulated by Dr. Bertoli and Dr. Reily

As seen in

What it feels like

You already know this feeling.

It's not dramatic. It's not an injury. It's the kind of thing that builds quietly, that moment of hesitation before you get up from the couch. Knuckles that feel stiff for the first hour. A knee that aches when it rains.

Most people in their 50s and 60s accept this as just getting older. What is actually happening underneath is an inflammatory process, and it tends to go unaddressed, partly because the things we reach for either don't work well enough or come with their own problems.

What people try first

IbuprofenWorks short-term. Kidney and stomach risk.
CBD oils or topicalsLittle absorption. Little effect.
Fish oil and turmericGood baseline habits. They don't inhibit COX-2 directly.

The difference

Why regular CBD probably didn't do much

Standard CBD

Produced by heating hemp, which destroys the natural CBDA.
Absorbed weakly by the body.
No meaningful COX-2 inhibition documented.
Works mostly at the receptor level.

Natural Dos CBDA

Preserved through low-temperature purification, so CBDA stays intact.
Absorbed over 500% more effectively than CBD.
Directly inhibits COX-2, the enzyme driving inflammatory pain.
Works at the enzyme, receptor and nerve level at once.

How it works

What is actually happening in your body

Interrupts inflammation at the source

CBDA directly inhibits COX-2, the enzyme your body uses to make inflammatory prostaglandins. Unlike ibuprofen it does this selectively, targeting the inflammatory pathway while leaving the stomach-protective COX-1 pathway mostly alone.

Quiets the pain signal at the nerve

CBDA acts on TRPV1, the ion channel on sensory nerves that works as the pain gate. Chronic inflammation keeps that gate stuck open. CBDA gradually desensitizes it, raising the threshold back toward normal, which is why the effect tends to build over time.

Reduces immune-driven inflammation

CBDA suppresses the pro-inflammatory cytokines TNF-alpha and IL-6 that keep the inflammatory cycle running. That deeper mechanism makes CBDA relevant not just for comfort but for the ongoing immune activity behind joint tissue breakdown.

Real customers

Hear it from them.

Ready when you are

Start with the one most people start with.

Choose mine

100-day money-back guarantee. Free US shipping on orders of $70 and over.

Scientific references (20)
ACS Chemistry for Life
British Pharmacological Society
PAIN Journal
Springer
Scientific Reports
Nature Portfolio
1. Formato, M. et al. (2020). Cannabidiolic-Acid (CBDA): A Unique Compound of Cannabis. Molecules, 25(21), 4936.
2. Bolognini, D. et al. (2013). Cannabidiolic acid prevents vomiting in Suncus murinus and nausea-induced behaviour in rats by enhancing 5-HT1A receptor activation. British Journal of Pharmacology, 168(6), 1456–1470.
3. Rock, E.M. et al. (2020). Cannabidiol and cannabidiolic acid reduce nausea and vomiting. Cannabis and Cannabinoid Research, 5(3), 191–198.
4. Takeda, S. et al. (2008). Cannabidiolic acid as a selective cyclooxygenase-2 inhibitory component in cannabis. Drug Metabolism and Disposition, 36(9), 1917–1921.
5. Rock, E.M. et al. (2018). Effect of cannabidiolic acid and ∆9-tetrahydrocannabinol on carrageenan-induced hyperalgesia and edema. Psychopharmacology, 235, 3259–3271.
6. Anderson, L.L. et al. (2019). Pharmacokinetics of phytocannabinoid acids and anticonvulsant effect of cannabidiolic acid in a mouse model of Dravet Syndrome. Journal of Natural Products, 82(11), 3047–3055.
7. Pertwee, R.G. et al. (2018). Cannabidiolic acid methyl ester, a stable synthetic analogue of cannabidiolic acid, can produce 5-HT1A receptor-mediated suppression of nausea. British Journal of Pharmacology, 175(1), 100–112.
8. Zhu, H.J. et al. (2006). Characterization of P-glycoprotein inhibition by major cannabinoids from marijuana. Journal of Pharmacology and Experimental Therapeutics, 317(3), 850–857.
9. Pellesi, L. et al. (2018). European Journal of Clinical Pharmacology: Pharmacokinetics and tolerability of oral cannabis preparations in patients with medication overuse headache.
10. Ujváry, I. & Hanuš, L. (2016). Human metabolites of cannabidiol: A review on their formation, biological activity, and relevance in therapy. Cannabis and Cannabinoid Research, 1(1), 90–101.
11. Rock, E.M. & Parker, L.A. (2013). Effect of low doses of cannabidiolic acid and ondansetron on LiCl-induced conditioned gaping in rats. British Journal of Pharmacology, 169(3), 685–692.
12. Takeda, S. et al. (2014). Down-regulation of cyclooxygenase-2 (COX-2) by cannabidiolic acid in human breast cancer cells. Journal of Toxicological Sciences, 39(5), 711–716.
13. De Petrocellis, L. et al. (2011). Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. British Journal of Pharmacology, 163(7), 1479–1494.
14. Navarro, G. et al. (2020). Cannabigerol action at cannabinoid CB1 and CB2 receptors and CB1–CB2 heteroreceptor complexes. Frontiers in Pharmacology, 11, 422.
15. Shannon, S. et al. (2019). Cannabidiol in anxiety and sleep: A large case series. The Permanente Journal, 23, 18–041.
16. Suraev, A.S. et al. (2020). Cannabinoid therapies in the management of sleep disorders: A systematic review of preclinical and clinical studies. Sleep Medicine Reviews, 53, 101339.
17. Kesner, A.J. & Lovinger, D.M. (2020). Cannabinoids, endocannabinoids and sleep. Frontiers in Molecular Neuroscience, 13, 125.
18. Murillo-Rodriguez, E. et al. (2006). Anandamide modulates sleep and memory in rats. Brain Research, 1075(1), 108–115.
19. Pacher, P. et al. (2006). The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacological Reviews, 58(3), 389–462.
20. Russo, E.B. (2011). Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. British Journal of Pharmacology, 163(7), 1344–1364.

NaturalDos™ is not endorsed by, sponsored by, or affiliated with any of these organizations.